ID   Mino
AC   CVCL_1872
SY   MINO
DR   EFO; EFO_0022501
DR   AddexBio; C0003033/4947
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-3000
DR   BioSample; SAMN03471705
DR   BioSample; SAMN10988480
DR   cancercelllines; CVCL_1872
DR   Cell_Model_Passport; SIDM01667
DR   ChEMBL-Cells; CHEMBL4523520
DR   ChEMBL-Targets; CHEMBL4523551
DR   Cosmic; 2078181
DR   Cosmic; 2088019
DR   Cosmic; 2756236
DR   DepMap; ACH-000220
DR   DSMZ; ACC-687
DR   DSMZCellDive; ACC-687
DR   GEO; GSM629496
DR   GEO; GSM629497
DR   GEO; GSM887321
DR   GEO; GSM888397
DR   GEO; GSM907522
DR   GEO; GSM1044970
DR   GEO; GSM1044971
DR   GEO; GSM1044972
DR   GEO; GSM1044973
DR   GEO; GSM1670110
DR   GEO; GSM2322625
DR   IARC_TP53; 17152
DR   LiGeA; CCLE_916
DR   Lonza; 165
DR   PharmacoDB; Mino_932_2019
DR   Progenetix; CVCL_1872
DR   PubChem_Cell_line; CVCL_1872
DR   Wikidata; Q54905748
RX   PubMed=12127561;
RX   PubMed=12683869;
RX   PubMed=21746927;
RX   PubMed=22460905;
RX   PubMed=24362935;
RX   PubMed=25315077;
RX   PubMed=25355872;
RX   PubMed=25688540;
RX   PubMed=25960936;
RX   PubMed=26194763;
RX   PubMed=28196595;
RX   PubMed=29666304;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 72 hours (PubMed=25315077); ~50 hours (DSMZ=ACC-687).
CC   HLA typing: A*11:01,68:01; B*35:01,39:01; C*04:01,12:03; DQA1*01:02,01:02; DQB1*05:01,06:03; DRB1*01:01,13:01 (PubMed=25960936).
CC   HLA typing: A*11,68; B*35,39; C*04,12 (PubMed=25688540).
CC   HLA typing: A*11:01:01,68:01:01; B*35:01:01,39:01:01; C*04:01:01,12:03:01; DPA1*01:03:01,02:01:01; DPB1*10:01:01,10:01:01; DQA1*01:03:01,01:01:01; DQB1*05:01:01,06:03:01; DRA*01:01:01,01:02:02; DRB1*01:01:01,13:01:01 (DSMZCellDive=ACC-687).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Lys (c.262G>A); ClinVar=VCV000821566; Zygosity=Homozygous (DepMap=ACH-000220).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Heterozygous (DepMap=ACH-000220).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val147Gly (c.440T>G); Zygosity=Homozygous (DepMap=ACH-000220).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=0.85%; Native American=0%; East Asian, North=1.5%; East Asian, South=0%; South Asian=6.1%; European, North=39.56%; European, South=51.98% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): AddexBio=C0003033/4947; ATCC=CRL-3000; DSMZ=ACC-687
ST   Amelogenin: X,Y
ST   CSF1PO: 9,11
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 12,14
ST   D19S433: 15
ST   D21S11: 29,30
ST   D2S1338: 23
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 23,25
ST   Penta D: 12,13
ST   Penta E: 5,17
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 35
//
RX   PubMed=12127561; DOI=10.1016/S0145-2126(02)00013-9;
RA   Lai R., McDonnell T.J., O'Connor S.L., Medeiros L.J., Oudat R.I.,
RA   Keating M.J., Morgan M.B., Curiel T.J., Ford R.J. Jr.;
RT   "Establishment and characterization of a new mantle cell lymphoma cell
RT   line, Mino.";
RL   Leuk. Res. 26:849-855(2002).
//
RX   PubMed=12683869; DOI=10.5858/2003-127-0424-COMCLC;
RA   Amin H.M., McDonnell T.J., Medeiros L.J., Rassidakis G.Z.,
RA   Leventaki V., O'Connor S.L., Keating M.J., Lai R.;
RT   "Characterization of 4 mantle cell lymphoma cell lines. Establishment
RT   of an in vitro study model.";
RL   Arch. Pathol. Lab. Med. 127:424-431(2003).
//
RX   PubMed=21746927; DOI=10.1073/pnas.1018941108; PMCID=PMC3145731;
RA   Beltran E., Fresquet V., Martinez-Useros J., Richter-Larrea J.A.,
RA   Sagardoy A., Sesma I., Almada L.L., Montes-Moreno S., Siebert R.,
RA   Gesk S., Calasanz M.J., Malumbres R., Rieger M., Prosper F.,
RA   Lossos I.S., Piris M.A., Fernandez-Zapico M.E.,
RA   Martinez-Climent J.A.;
RT   "A cyclin-D1 interaction with BAX underlies its oncogenic role and
RT   potential as a therapeutic target in mantle cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:12461-12466(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24362935; DOI=10.1038/nm.3435;
RA   Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chan F.C.,
RA   Meissner B., Bhang H.-E.C., Ruddy D., Kauffmann A., Farsidjani A.,
RA   Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S.,
RA   Dietze K., Dorken B., Steidl C., Tzankov A., Hummel M., Monahan J.E.,
RA   Morrissey M.P., Fritsch C., Sellers W.R., Cooke V.G., Gascoyne R.D.,
RA   Lenz G., Stegmeier F.;
RT   "Pharmacological and genomic profiling identifies NF-kappaB-targeted
RT   treatment strategies for mantle cell lymphoma.";
RL   Nat. Med. 20:87-92(2014).
//
RX   PubMed=25315077; DOI=10.3109/10428194.2014.970548;
RA   Fogli L.K., Williams M.E., Connors J.M., Reid Y.A., Brown K.,
RA   O'Connor O.A.;
RT   "Development and characterization of a Mantle Cell Lymphoma Cell Bank
RT   in the American Type Culture Collection.";
RL   Leuk. Lymphoma 56:2114-2122(2015).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26194763; DOI=10.1182/blood-2015-01-624585; PMCID=PMC4582332;
RA   Bhatt S., Matthews J., Parvin S., Sarosiek K.A., Zhao D.-K., Jiang X.-Y.,
RA   Isik E., Letai A.G., Lossos I.S.;
RT   "Direct and immune-mediated cytotoxicity of interleukin-21 contributes
RT   to antitumor effects in mantle cell lymphoma.";
RL   Blood 126:1555-1564(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C.,
RA   Yang H.H., Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//